ADAG ADAG
Company Profile ↓Company Overview
ADAG (ADAG) is a publicly traded company listed on with a market capitalization of $250.55M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 26.0% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Dec 2025 Revenue of $7.67M (+7332.8% YoY); net profit $-17.61M.
- 5-Year Trend Long-term compounding — revenue CAGR -6.2%, profit CAGR 26.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -6.19% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 25.99% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +78.48% |
| 6 Months: | +43.39% |
| 3 Months: | +16.85% |
| 1 Month: | +7.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 26.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -6.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 9.29M | 18.11M | 103.20K | 7.67M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 93.21M | 41.83M | 36.05M | 29.11M |
| Operating Income | - | -83.92M | -23.72M | -35.95M | -21.44M |
| EBITDA | - | -77.37M | -14.94M | -31.65M | -16.85M |
| Interest Expense | - | 693.32K | 1.11M | 851.87K | 463.13K |
| Pretax Income | - | -79.51M | -17.25M | -33.44M | -17.91M |
| Tax Provision | - | 459.06K | 1.69M | -17.55K | -297.86K |
| Net Income | - | -79.97M | -18.95M | -33.42M | -17.61M |
| Diluted EPS | -1.82 | -1.85 | -0.44 | -0.74 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 152.40M | 115.73M | 89.27M | 78.26M |
| Current Assets | - | 149.32M | 113.44M | 87.78M | 77.38M |
| Cash & Equivalents | - | 143.76M | 109.93M | 85.19M | 74.52M |
| Inventory | - | - | - | - | - |
| Receivables | 3.00M | 0 | - | - | - |
| Total Liabilities | - | 69.31M | 45.17M | 38.74M | 42.91M |
| Current Liabilities | - | 55.08M | 31.46M | 38.18M | 25.17M |
| Long Term Debt | - | 14.15M | 13.54M | 417.34K | 1.14M |
| Total Debt | - | 27.97M | 22.31M | 18.49M | 6.26M |
| Total Equity | - | 83.09M | 70.56M | 50.52M | 35.35M |
| Shares Outstanding | - | 54.07M | 55.15M | 58.89M | 59.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -48.61M | -28.45M | -29.70M | -15.66M |
| Investing Cash Flow | - | -686.05K | -77.36K | 1.11M | 476.80K |
| Financing Cash Flow | - | 17.82M | -5.37M | 3.77M | 4.45M |
| Capital Expenditure | - | -690.94K | -85.01K | -33.58K | -17.05K |
| Free Cash Flow | - | -49.30M | -28.54M | -29.73M | -15.67M |
| Net Change in Cash | - | -31.47M | -33.90M | -24.82M | -10.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -903.1% | -131.0% | -34,835.4% | -279.5% |
| Net Margin % | - | -860.6% | -104.6% | -32,386.4% | -229.6% |
| ROE % | - | -96.2% | -26.9% | -66.2% | -49.8% |
| ROCE % | - | -86.2% | -28.1% | -70.4% | -40.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HSG Holding Ltd | 2.83% | 1.34M | $5.68M |
| 2 | Exome Asset Management LLC | 1.55% | 736.85K | $3.12M |
| 3 | Ameriprise Financial, Inc. | 1.28% | 607.90K | $2.57M |
| 4 | Mill Creek Capital Advisors, LLC | 0.42% | 199.61K | $844.35K |
| 5 | Morgan Stanley | 0.14% | 66.15K | $279.81K |
| 6 | Invesco Ltd. | 0.10% | 47.12K | $199.33K |
| 7 | Smartharvest Portfolios, LLC | 0.09% | 40.31K | $170.52K |
| 8 | Kamunting Street Capital Management, L.P. | 0.08% | 38.07K | $161.04K |
| 9 | Persistent Asset Partners Ltd | 0.07% | 35.13K | $148.58K |
| 10 | Dauntless Investment Group, LLC | 0.07% | 34.77K | $147.10K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADAG
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s f…
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior manage…
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration wi…
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modifi…
ADAG — Frequently Asked Questions
What is the current share price of ADAG?
As of 2026-08-05 17:25 PDT, ADAG trades at $4.23 on NASDAQ/NYSE. Its 52-week range is $1.40 to $4.78.
What is the market capitalisation of ADAG?
ADAG has a market capitalisation of $250.55M on NASDAQ/NYSE.
What is the P/E ratio of ADAG?
ADAG trades at a trailing price-to-earnings (P/E) ratio of -5.74. Its price-to-book (P/B) ratio is 7.09.
What is the return on equity (ROE) of ADAG?
ADAG has a return on equity (ROE) of -49.82%. Its return on capital employed (ROCE) is -32.86%.
Is ADAG a good stock to buy?
This page provides a data-driven analysis of ADAG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.